Anika Therapeutics (NASDAQ:ANIK – Get Rating) and Alpha Tau Medical (NASDAQ:DRTS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Insider & Institutional Ownership
91.6% of Anika Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Alpha Tau Medical shares are held by institutional investors. 3.0% of Anika Therapeutics shares are held by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Get Anika Therapeutics alerts:Profitability
This table compares Anika Therapeutics and Alpha Tau Medical's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anika Therapeutics | -10.33% | -2.49% | -2.05% |
| Alpha Tau Medical | N/A | -49.72% | -33.76% |
Analyst Ratings
This is a summary of recent ratings and price targets for Anika Therapeutics and Alpha Tau Medical, as provided by MarketBeat.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
Anika Therapeutics currently has a consensus target price of $28.50, suggesting a potential downside of 7.05%. Alpha Tau Medical has a consensus target price of $17.67, suggesting a potential upside of 338.38%. Given Alpha Tau Medical's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Tau Medical is more favorable than Anika Therapeutics.
Risk & Volatility
Anika Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Earnings & Valuation
This table compares Anika Therapeutics and Alpha Tau Medical's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anika Therapeutics | $147.79 million | 3.03 | $4.13 million | ($1.09) | -28.13 |
| Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
Anika Therapeutics has higher revenue and earnings than Alpha Tau Medical.
Summary
Anika Therapeutics beats Alpha Tau Medical on 6 of the 11 factors compared between the two stocks.
About Anika Therapeutics
(Get Rating)
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
About Alpha Tau Medical
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.